Clinical comprehensive evaluation of proprotein convertase subtilisin kexin 9 monoclonal antibodies based on the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the 2nd edition)
MA Juan-juan
CHENG Jie
JU Xiao-yu
SUN Jie-wei
WANG Yun-huan
Abstract：Objective:To conduct a comprehensive analysis of proprotein convertase subtilisin kexin 9(PCSK9)monoclonal antibodies based on a multi-dimensional evaluation method,providing a reference for clinical medication selection and drug selection in medical institutions.Methods:Referring to the evaluation system in the Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions(the 2 nd edition),with appropriate adjustments to some scoring criteria,a quantitative assessment was conducted on six PCSK9 monoclonal antibodies available in the domestic market from five aspects:pharmaceutical characteristics,efficacy,safety,economy,and other attributes.The recommendation grades were determined based on the scoring results.Results:The quantitative scoring results,ranked from high to low,were as follows:evolocumab(79.31 points),alirocumab(74.85 points),tolersimab(73.86 points),recaticimab(71.95 points),ongericimab(70.9 points),and ebronucimab(70.88 points).Conclusion:All six PCSK9 monoclonal antibodies demonstrated good lipid-lowering efficacy.Among them,evolocumab,alirocumab,and tolersimab are strongly recommended,while the others are weakly recommended.
Keywords：PCSK9 monoclonal antibodydrug selectionevolocumabalirocumabtafolecimabebro-nucimabongericimabrecaticimab
Publication Date：2026-07-30
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：8( 1545-1552 )